---
title: "Ascentage Pharma Group International (06855.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/06855.HK.md"
symbol: "06855.HK"
name: "Ascentage Pharma Group International"
industry: "Biotechnology"
---

# Ascentage Pharma Group International (06855.HK)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | HK Market |
| Website | [www.ascentage.cn](https://www.ascentage.cn) |

## Company Profile

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including tho...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-16T04:30:10.000Z

**Overall: E (0.83)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 51 / 53 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -56.68% |  |
| Net Profit YoY | -222.23% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 24.28 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 17.73B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 423.48M |  |


**Multi Score**: E

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -161.85% | E |
| Profit Margin | -296.77% | E |
| Gross Margin | 90.74% | A |

#### Growth Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -56.68% | E |
| Net Profit YoY | -222.23% | E |
| Total Assets YoY | -0.14% | D |
| Net Assets YoY | -11.33% | D |

#### Cash Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -33.70% | D |
| OCF YoY | -56.68% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.13 | E |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 77.81% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Ascentage Pharma Group International",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-161.85%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-296.77%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "90.74%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "E",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-56.68%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-222.23%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-0.14%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-11.33%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "E",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-33.70%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-56.68%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.13",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "77.81%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | BEONE MEDICINES (HK.6160) | C | A | B | C | A | B |
| 02 | INNOVENT BIO (HK.1801) | B | A | C | B | A | B |
| 03 | 3SBIO (HK.1530) | A | B | C | A | C | B |
| 04 | BIOCYTOGEN-B (HK.2315) | A | A | C | D | B | B |
| 05 | HBM HOLDINGS-B (HK.2142) | A | A | C | B | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -13.71 | 38/70 | - | - | - |
| PB | 23.86 | 55/70 | 71.88 | 38.86 | 26.35 |
| PS (TTM) | 40.69 | 42/70 | 57.61 | 31.62 | 15.10 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-07T16:00:00.000Z

Total Analysts: **6**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 5 | 83% |
| Overweight | 1 | 17% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 46.68 |
| Highest Target | 113.98 |
| Lowest Target | 58.97 |

## References

- [Company Overview](https://longbridge.com/en/quote/06855.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/06855.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/06855.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.